It is not within the remit of this report to extol the features and coverage of commercial database products. This is done adequately via the company websites and publicity material but it is problematic that they rarely declare comparative entity intersect statistics with public sources (although as an unusual precedent this was permitted in PMID 22024215). However, CI products are important in the INS360 context and ADEV teams may have (or should contrive to get) access to at least some of them via their host institutions or collaborators. The licencing of SciFinder (SF) by many universities and research institutes means there is a high probability of team member access (perhaps even as their only available commercial database). The May 2019 announcement of their 150-millionth registered substance puts them ~52 million ahead of PubChem but still ~9 million behind UniChem. It is significant to note that SF increased by 50 million in four years compared to 34 million for PubChem. This suggests sustained global novel chemistry output that correlates with the sustained document growth in Fig 1 (and was confirmed via a different commercial database at least up to 2013 in PMID 24204758). One of the advantages of SF is the breadth of manually curated chemistryto-document connectivity. This exceeds public sources by a considerable margin, even though the extent of this is unknown (n.b. arguably the scale of SF puts it beyond being classified just as a CI product since many scientists use it as their primary chemistry and literature gateway). Thus, searching a lead series in SF to provide a comprehensive interrogation of chemistry, papers and patents in parallel should be an INS360 core task.